drugset / Trial / NCT00003877
Peripheral Stem Cell Transplantation With or Without Stromagen Following Chemotherapy in Treating Women With Metastatic Breast Cancer
Phase 1/2
Completed
30 enrolled
Roswell Park Cancer Institute
National Cancer Institute (NCI) · collab
RandomizedTreatment
Summary
RATIONALE: Peripheral stem cell transplantation may allow doctors to give higher doses of chemotherapy and kill more tumor cells. It is not yet known whether Stromagen improves the success of stem cell transplantation in women with breast cancer. PURPOSE: Randomized phase I/II trial to study the effectiveness of Stromagen during stem cell transplantation following chemotherapy in treating women with metastatic breast cancer.
Timeline
- Start
- 1998-09
- Primary completion
- 2000-02
- Completion
- 2000-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | Carboplatin | Small molecule | — | Intravenous |
| Background | Cyclophosphamide | Other / unclassified | — | Intravenous |
| Background | Paclitaxel | Small molecule | — | Intravenous |
| Background | Thiotepa | Other / unclassified | — | Intravenous |
| Background | filgrastim | Protein / enzyme biologic | — | Subcutaneous |